Philipps-University Marburg

Philipps-University Marburg (UNIMAR), Institute of Virology

Founded in 1527, the Philipps-Universität Marburg is a traditional German university of approximately 19,000 students. It has been a place of research and teaching for nearly five centuries. The university relies on innovative teaching methods (with short course durations) and networked research, and offers students from all over the world a broad range of courses.

The Philipps-Universität Marburg’s greatest strengths in research lie in medicine, infectious disease, tumour research, microbiology, neurosciences as well as peace and conflict research, other natural sciences such as material sciences, and arts. The Philipps-Universität Marburg has been a successful partner and coordinator in numerous European Collaborative Projects, Networks of Excellence and 4 European Research Council (ERC) grants.

The Institute of Virology has a long-standing interest in human and animal influenza viruses. It has made major contributions to the understanding of the molecular mechanisms involved in pathogenesis, interspecies transmission, and host range. Staff has a broad spectrum of expertise in classical virology techniques, reversed genetics, and animal experimentation.

The institute has been involved in the identification and molecular characterization of the first German isolates of the new H1N1 influenza virus. The institute is located in a new building that includes BSL2 (bio-safety level), BSL3, and BSL4 laboratories, and collaborates closely with other departments of the Medical School of UNIMAR and with the nearby Max-Planck-Institute of Terrestrial Microbiology. The Institute of Virology has been a partner in several EU projects including VIRGIL, FLUINNATE, FLUPATH, FLUPOL and ESNIP.


Hans-Dieter Klenk | MD

Professor emeritus and former director of the Institute of Virology of PUM. Extensive research expertise has encompassed structure, function and biosynthesis of the glycoproteins and the polymerase of influenza viruses in relation to pathogenicity, host range, and the development of antiviral treatments. He has extensive expertise in co-ordinating or participating to large research projects at national and international levels, including VIRGIL and FLUPOL.